Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8317937 | 0.94 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1LMNATSHRHSD17B10 | |
| SCHEMBL15800765 | 0.94 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1LMNATSHRHSD17B10 | |
| SCHEMBL2349522 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1LMNATSHRHSD17B10 | |
| SCHEMBL12191374 | 0.87 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1LMNATSHRHSD17B10 | |
| SCHEMBL2340586 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1LMNATSHRHSD17B10 | |
| SCHEMBL10928501 | 0.84 | CYP4F2 (0.39) | SMN1; SMN2ALDH1A1LMNATSHRHSD17B10 | |
| SCHEMBL12125197 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1LMNATSHRHSD17B10 | |
| SCHEMBL2347979 | 0.84 | LMNA (0.65) | SMN1; SMN2ALDH1A1LMNATSHRHSD17B10 | |
| SCHEMBL19114877 | 0.84 | LMNA (0.65) | SMN1; SMN2ALDH1A1LMNATSHRHSD17B10 | |
| SCHEMBL29302167 | 0.84 | LMNA (0.65) | SMN1; SMN2ALDH1A1LMNATSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017015109-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2016205323-A1 | POLYNUCLEOTDE AGENTS TARGETING HYDROXYACID OXIDASE (GLYCOLATE OXIDASE, HAO1) AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016168286-A1 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-9370582-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370581-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9352048-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9290760-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150119444-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | BANK OF AMERICA, N.A. | 2015-04-30 | — | — | US | disclosed |
| US-20150119445-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | BANK OF AMERICA, N.A. | 2015-04-30 | — | — | US | disclosed |
| US-20150011615-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | BANK OF AMERICA, N.A. | 2015-01-08 | — | — | US | disclosed |
| US-8828956-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140179761-A1 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20130178512-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2013-07-11 | — | — | US | disclosed |
| US-8450467-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| WO-2012177947-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) GENES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2012-05-31 | — | — | US | disclosed |
| US-8106022-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178512-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | SMN1; SMN2 3506/4885ALDH1A1 4231/4885LMNA 266/4885 |
| US-20150119445-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | LPXN, ZYX, OSTC | SMN1; SMN2 3469/4885ALDH1A1 4381/4885LMNA 271/4885 |
| US-20140179761-A1 | TARGETING LIPIDS | LY96, ABHD10, APOB | SMN1; SMN2 2040/4885ALDH1A1 1600/4885LMNA 169/4885 |
| US-20150011615-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | LPXN, ZYX, OSTC | SMN1; SMN2 3489/4885ALDH1A1 4251/4885LMNA 274/4885 |
| US-20150119444-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | LPXN, ZYX, OSTC | SMN1; SMN2 3489/4885ALDH1A1 4251/4885LMNA 274/4885 |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | SMN1; SMN2 3506/4885ALDH1A1 4231/4885LMNA 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.